Carna Biosciences

4572.TTSE GROWTHPharmaceutical

Key numbers · FY ended 2025-12

Revenue¥579m-9.0% YoY Operating income−¥2.1bn—Net income (owners)−¥2.2bn—Total assets¥1.2bn-55.6% YoY EPS (basic)¥-113.62+6.6% YoY

Full financial history and reports →

Stock price4572 · View chart ↗

Open the price chart on TradingView.

Latest filings

Mon, Nov 9 · JST1 filing

12:515% STAKECarna Biosciences · Cantor Fitzgerald Europe · 24.57% → 25.99%+1.42pp

Fri, Nov 6 · JST1 filing

13:275% STAKECarna Biosciences · Cantor Fitzgerald Europe · 25.65% → 24.57%−1.08pp

Tue, Oct 20 · JST1 filing

14:325% STAKECarna Biosciences · Gomi Daisuke · 6.66% → 13.68%+7.02pp

Mon, Oct 19 · JST1 filing

14:395% STAKECarna Biosciences · Cantor Fitzgerald Europe · 27.24% → 25.65%−1.59pp

Wed, Oct 14 · JST1 filing

17:135% STAKECarna Biosciences · Gomi Daisuke · 5.14% → 6.66%+1.52pp

All filings →

Major holders (5%+) · 2

Holder	Stake	Change	Filed
Cantor Fitzgerald Europe	25.99%	+1.42pp	2026-11-09
Gomi Daisuke	13.68%	+7.02pp	2026-10-20

Each holder's own ratio from its most recent large-shareholding report.